Exploring gaps in GLP-1 research, care, and coverage

Healthcare Strategies

Xtelligent Healthcare Media에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Xtelligent Healthcare Media 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

1M ago 16:35

MP3•에피소드 홈

GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.

Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.

In today’s episode, we’ll cover

The significant progress made in GLP-1 research, care delivery, and insurance coverage
Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management

And more!

To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies

Resources:

120 에피소드

#Business #Healthcare Strategies #Xtelligent Healthcare Media